Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
http://www.reportlinker.com/p0619272/Healthcare-Acquired-Infection-Devices-Pharmaceuticals-and-Environmental-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
REPORT HIGHLIGHTS
* The global market for healthcare-acquired infection treatments were $16 billion in year 2010. This market is estimated to be around $19 billion in the year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of 9.5% for five year period.
* Markets for infection control devices and products were $8.3 billion in the year 2010 and are expected to reach $10.3 billion by 2011. This market is forecasted to cross $18.3 billion by 2016 at a CAGR of 12%.
* The market for pharmaceutical treatments is expected to be around $4.5 billion. This market is expected to increase at a 5.8% compound annual growth rate (CAGR) to reach $6 billion by 2016.
INTRODUCTION
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of the selected areas of the global healthcare-acquired infection (HAI) market. HAI is sometimes used to mean hospital-acquired infections, but for purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers, and dialysis centers. Another term for healthcare-acquired infections is nosocomial infections.
The focus of this report is on devices, pharmaceuticals, and therapies currently used or under development for treatment of viral, bacterial, or fungal infections.
The global market for HAI products is estimated at between $10 billion and $15 billion in 2010, depending on the products included in the study, with high single-digit growth through 2016. Although the U.S. holds between 45% and 50% of the market, the fastest-growing regions for HAI treatments are the Asia-Pacific, which includes China, and Brazil.
STUDY GOALS AND OBJECTIVES
Healthcare-acquired infections are viral, bacterial, or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters, and intravenous lines.
The Centers for Disease Control (CDC) estimates that 2 million HAIs occur annually in the U.S. This leads to 100,000 deaths and costs an additional $36 billion to $45 billion in direct medical costs annually.
This report is designed to investigate the global HAI market by treatment area and by treatment type, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China.
This report offers forecasts of the markets for devices, pharmaceuticals, and therapies by treatment segment and treatment type from 2011 through 2016, including supporting analyses for projections.
This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
This is an invaluable tool for business planners; acquisition specialists; licensing strategists; product managers; market research analysts; investing consultants; and others interested in the HAI market, its products, its participants, and its future.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was obtained from various primary and secondary research sources, including industry analysts, annual reports, Securities and Exchange Commission (SEC) reports, the World Health Organization (WHO), the National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS), government agencies outside the U.S, and journal articles. Secondary sources include literature searches, product literature, and press releases.
When precise information was unavailable, a consensus is made using reasonable assumptions and estimates based on historical data.
CHAPTER ONE: INTRODUCTION 1
REASONS FOR DOING THE STUDY 1
STUDY GOALS AND OBJECTIVES 1
METHODOLOGIES AND INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER TWO: SUMMARY 4
SUMMARY (CONTINUED) 4
SUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS,
THROUGH 2016 ($ MILLIONS) 5
SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BY
GEOGRAPHICAL AREA, 2010 AND 2016 (%) 6
CHAPTER THREE: OVERVIEW 7
TABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED
INFECTIONS (PER 100 PATIENTS) 7
TABLE 1 (CONTINUED) 8
IMPORTANCE OF HAND WASHING 8
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS 9
TABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED
INFECTIONS 9
TABLE 2 (CONTINUED) 10
GRAM-POSITIVE BACTERIA 10
S AUREUS 11
Transmission Routes 11
MRSA 11
Rate of Infection 11
Transmission Routes 12
TYPES OF PNEUMONIA 13
Pseudomonas Aeruginosa 13
Hospital-Acquired Pneumonia 13
Klebsiella Pneumonia 13
CLOSTRIDIUM DIFFICILE 14
MYCOBACTERIUM TUBERCULOSIS 14
Scope of Infection 14
E COLI 15
UTI Treatment Options 15
GASTROENTERITIS-CAUSING BACTERIA 15
Treatment Options 16
VANCOMYCIN-RESISTANT ENTEROCOCCI 16
Types of VRE 16
LEGIONELLA BACTERIA 16
Treatment Options 17
GRAM-NEGATIVE BACTERIA 17
PSEUDOMONAS AERUGINOSA 17
ACINETOBACTER BAUMANNII 18
STENOTROPHOMONAS MALTOPHILIA 18
VIRAL INFECTIONS 19
VIRAL INFECTION RESEARCH 19
HEPATITIS B AND C 19
Scope of Infection 20
Treatment 20
HIV 20
Treatment 21
NOROVIRUS 21
INFLUENZA VIRUS 21
Influenzavirus A, B, C 21
Transmission 22
Symptoms 22
Treatment 22
RESPIRATORY SYNCYTIAL VIRUS 23
Treatment 23
FUNGAL INFECTIONS 23
ASPERGILLUS INFECTIONS 23
Treatment 24
YEAST INFECTIONS 24
Candida Infections 24
PREVENTING HAI 25
DETERMINING THE MODE OF TRANSMISSION 25
CDC RECOMMENDATIONS FOR PREVENTION 26
TABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCAREACQUIRED
INFECTIONS, 2007 26
TABLE 3 (CONTINUED) 27
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION
CONTROL INDIVIDUALS 27
TABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL
TEAM MEMBERS 28
TABLE 4 (CONTINUED) 29
COMPONENTS OF A HAI SURVEILLANCE SYSTEM 30
TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN
EFFECTIVE INFECTION-CONTROL SURVEILLANCE SYSTEM 30
SUITABLE SURVEYS IN DEVELOPING COUNTRIES 30
HEALTHCARE INFECTION POINTS OF GENERATION 31
HOSPITALS 31
SURGICAL PROCEDURES 31
AMBULATORY SURGERY CENTERS IN THE US 31
Number of Procedures in ASCs 32
Infection Control in ASCs 32
DIALYSIS CENTERS 32
US Dialysis Centers 32
Transmission of VRE 33
Hepatitis Transmission in US Dialysis Centers 33
Hepatitis Transmission in Dialysis Centers Outside the
US 33
ASSISTED LIVING AND LONG-TERM CARE FACILITIES 34
TREATMENTS 34
PROACTIVE MEASURES 34
Environmental Controls 35
Device Design 35
REACTIVE MEASURES 35
CHANGES IN THE INDUSTRY 35
TABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005–2011
($ MILLIONS) 36
CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTION
MARKET 37
US MARKET 37
US HEALTHCARE SPENDING 37
SCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN US 38
Ventilator-Associated Pneumonia 38
RATE OF INFECTION 39
Intensive Care Units 39
Surgical Site Infections 39
Fungal Infections 40
COSTS 40
US PREVENTION ACTION PLAN 41
TABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (%
REDUCTION) 41
EUROPEAN MARKET 42
SCOPE 42
HELICS 42
RATE OF INFECTION AND COSTS 42
JAPANESE MARKET 43
SCOPE 43
RATE OF INFECTION 44
CHINESE MARKET 45
SCOPE 45
RATE OF INFECTION 45
REST OF THE WORLD MARKET 45
SCOPE 46
RATE OF INFECTION 46
Rate of Infection (Continued) 47
OPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRY 48
MEDICAL DEVICE OPPORTUNITIES AND CHALLENGES 48
Challenges 48
ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES
AND CHALLENGES 49
Challenges 49
NEW TREATMENTS 49
PHARMACEUTICAL MARKET OPPORTUNITIES AND
CHALLENGES 49
Patent Expiry 50
TABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT
EXPIRATIONS, 2005–2020 50
Pipeline Limitations 50
Global Recession 51
Regulatory Restrictions 51
Generic Competition 51
IMPACT OF DEMOGRAPHIC CHANGES 52
DEMOGRAPHIC CHANGES IN THE US 52
DEMOGRAPHIC CHANGES OUTSIDE THE US 52
Demographic Changes Outside the US (Continued) 53
CHAPTER FIVE: HAI PHARMACEUTICAL MARKET 54
GLOBAL MARKETS 54
ROLE OF EMERGING NATIONS 54
PHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED
INFECTIONS 55
TABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,
THROUGH 2016 ($ MILLIONS) 55
GLOBAL GROWTH RATES FOR PHARMACEUTICALS 55
TABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL
HEALTHCARE SPENDING BY REGION, THROUGH 2016 (%) 56
VIRAL HAI PHARMACEUTICALS 56
TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME,
INDICATION, AND MANUFACTURER, 2010 57
FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR
PRESCRIPTION PHARMACEUTICALS TO TREAT VIRAL HAI BY
COMPANY, 2010 (%) 58
FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%) 59
VIRAL PHARMACEUTICAL MARKET BY CONDITION 59
TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT
VIRAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS) 60
BACTERIAL HAI PHARMACEUTICALS 60
TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY
NAME, INDICATION, AND MANUFACTURER, 2010 60
TABLE 13 (CONTINUED) 61
DRUG CLASSES 61
Aminoglycosides 62
B-Lactam Antibiotics 62
Cephalosporins 62
Glycopeptides 63
Lincosamides 63
Lipopeptides 63
Carbapenems 63
Penicillins 64
Polypeptides 64
Macrolides 65
Quinolones 65
Tetracyclines 65
Tuberculosis 65
Sulfonamides 65
Other Formulations 65
FIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION
PHARMACEUTICALS TO TREAT BACTERIAL HAI BY COMPANY,
2010 (%) 66
TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT
BACTERIAL HAI, THROUGH 2016 ($ MILLIONS) 67
TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT
BACTERIAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS) 68
FUNGAL HAI PHARMACEUTICALS 68
TABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT
FUNGAL INFECTIONS BY NAME, TYPE, AND MANUFACTURER,
2010 68
TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT
FUNGAL HAI, THROUGH 2016 ($ MILLIONS) 69
FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL
HAI BY COMPANY, 2010 (%) 70
GLOBAL OPPORTUNITIES 70
CHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKET 71
GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET 71
TABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED
INFECTIONS, THROUGH 2016 ($ MILLIONS) 71
PLANNING FOR CONSTRUCTION OR RENOVATION: US 72
Plans Involving Infection Control 72
AIR TREATMENT 72
ROOM FILTRATION SYSTEMS 73
ROOM PRESSURIZATION 74
HYDROGEN PEROXIDE VAPOR 74
Dedicated Airborne Isolation Rooms 75
WATER TREATMENT 75
DESIGN OF SINKS AND OTHER WATER FACILITIES 75
CLEANING PHYSICAL SURFACES 75
DISINFECTION 76
Advantages and Disadvantages of Disinfectants 76
TABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY
USED DISINFECTANTS 77
TABLE 19 (CONTINUED) 78
PHENOLICS 78
OXIDIZING AGENTS 78
HALOGENS 79
ALDEHYDES 79
QUATERNARY AMINES 79
ALCOHOLS 80
TABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED
INFECTIONS, THROUGH 2016 ($ MILLIONS) 80
FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY
TYPE, 2010 (%) 80
FIGURE 5 (CONTINUED) 81
PATIENT SKIN PREPARATION DISINFECTANTS 81
IODINE 81
POVIDONE-IODINE SOLUTIONS 82
CHLORHEXIDINE GLUCONATE 82
TABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION
DISINFECTANTS, THROUGH 2016 ($ MILLIONS) 82
STERILIZATION SYSTEMS FOR INFECTION CONTROL 83
TABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO
MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH
2016 ($ MILLIONS) 83
CHEMICAL STERILIZATION 84
ETO Sterilization 84
Major Players in Chemical Sterilization 85
OTHER CHEMICAL STERILIZATION 85
Peracetic Acid 85
Hydrogen Peroxide 85
Chlorine Dioxide 86
Ozone 86
STEAM STERILIZATION 86
TABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL
TO STEAM STERILIZATION 87
Autoclaving 87
Major Players in Heat Sterilization 88
CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENT
VENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERS 89
SELECTED GLOBAL MEDICAL HAI DEVICE MARKET 89
TABLE 24 GLOBAL MARKET FOR MEDICAL DEVICES THAT
MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH
2016 ($ MILLIONS) 90
CATHETERS 90
USE OF COATINGS 91
CATHETER COATINGS 91
TABLE 25 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC
PROPERTIES 91
Silver Coating 92
SURFACE-MODIFIED CATHETER 92
TABLE 26 GLOBAL MARKET FOR CATHETERS WITH
ANTIMICROBIAL PROPERTIES, THROUGH 2016 ($ MILLIONS) 93
FIGURE 6 HAI CATHETER MARKET SHARES BY URINARY, CVC,
PICC, AND OTHER SEGMENTS, 2011 AND 2016 (%) 93
FIGURE 6 (CONTINUED) 94
URINARY TRACT CATHETERS 94
CENTRAL VENOUS CATHETERS 94
Dialysis Catheters 95
Catheter-Related Bloodstream Infections 95
Catheter-Related Bloodstream Infections
(Continued) 96
TABLE 27 POTENTIAL SOURCES OF CRBSI 97
PERIPHERALLY INSERTED CENTRAL VENOUS
CATHETERS 97
MARKET OPPORTUNITIES FOR CATHETER
MANUFACTURERS 97
CATHETER GROWTH IN REGIONAL MARKETS 98
TABLE 28 GLOBAL HAI CATHETER MARKET BY REGION,
THROUGH 2016 ($ MILLIONS) 98
FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND
2016 (%) 99
PATIENT VENTILATION DEVICES 100
TABLE 29 GLOBAL MARKET FOR PATIENT VENTILATION
PRODUCTS, THROUGH 2016 ($ MILLIONS) 100
TYPES OF VENTILATION DEVICES 101
Non-Invasive Ventilators 101
TABLE 30 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS
SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAIS,
THROUGH 2016 ($ MILLIONS) 102
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS 102
Coated Endotracheal Tubes 102
Tapered Endotracheal Tubes 103
TABLE 31 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES
DESIGNED TO MINIMIZE VAP, THROUGH 2016 ($ MILLIONS) 103
IN-LINE STERILE IV FILTRATION 103
TABLE 32 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 ($
MILLIONS) 104
CHAPTER EIGHT: REGULATIONS AND PATENTS 105
US INFECTION CONTROL PROGRAMS 105
INFECTION CONTROL MEASURES AND PROTOCOLS 106
US REGULATIONS 106
HOSPITAL INFECTIONS DISCLOSURE ACT 106
CURRENT AND PENDING REQUIREMENTS 106
Affordable Care Act and Implications for the
Pharmaceutical Industry 107
Biosimilars 107
CMS Reimbursement for HAIs 108
EUROPEAN REGULATIONS 108
IMPLICATIONS FOR PHARMACEUTICAL
MANUFACTURERS 108
JAPANESE REGULATIONS 109
CHINESE REGULATIONS 110
PATENTS 110
PATENTS BY MANUFACTURER 110
TABLE 33 PATENTS BY MANUFACTURER, 2005–2011 111
TABLE 33 (CONTINUED) 112
TABLE 33 (CONTINUED) 113
PATENTS BY DATE OF ISSUE 113
TABLE 34 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005–
2011 114
TABLE 34 (CONTINUED) 115
PATENTS BY MANUFACTURER 115
TABLE 35 PATENTS BY MANUFACTURER 115
TABLE 35 (CONTINUED) 116
PATENTS FOR DELIVERY OF PHARMACEUTICALS 117
TABLE 36 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY,
2005–2011 117
BACTERIAL PHARMACEUTICAL PATENTS 117
TABLE 37 PATENTS BY INDICATION: BACTERIAL
PHARMACEUTICAL, 2005–2011 118
TABLE 37 (CONTINUED) 119
TABLE 37 (CONTINUED) 120
TABLE 37 (CONTINUED) 121
FUNGAL PHARMACEUTICAL PATENTS 121
TABLE 38 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL,
2010 121
VIRAL PHARMACEUTICAL PATENTS 122
TABLE 39 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL,
2005–2011 122
TABLE 39 (CONTINUED) 123
TABLE 39 (CONTINUED) 124
ENVIRONMENTAL CONTROLS 125
TABLE 40 PATENT BY INDICATION: AIR FILTRATION, 2005–2011 125
TABLE 41 PATENTS BY INDICATION: WATER TREATMENT, 2005–
2011 126
PATENTS FOR SURFACE DISINFECTANTS 126
TABLE 42 PATENTS BY INDICATION: DISINFECTANT SURFACES,
2005–2011 127
TABLE 42 (CONTINUED) 128
TABLE 42 (CONTINUED) 129
TABLE 43 PATENT BY INDICATION: SOLID WASTE TREATMENT,
2005–2011 130
PATENTS FOR DIAGNOSTIC PROCESSES 130
TABLE 44 PATENTS BY INDICATION: DIAGNOSTIC, 2006–2011 131
TABLE 44 (CONTINUED) 132
MEDICAL DEVICES 132
TABLE 45 PATENTS BY INDICATION: CATHETER, 2008–2011 132
TABLE 45 (CONTINUED) 133
TABLE 45 (CONTINUED) 134
TABLE 45 (CONTINUED) 135
TABLE 46 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS,
2005–2011 135
TABLE 46 (CONTINUED) 136
TABLE 46 (CONTINUED) 137
TABLE 46 (CONTINUED) 138
TABLE 46 (CONTINUED) 139
TABLE 46 (CONTINUED) 140
CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIES 141
EMERGING RESEARCH 141
RAPID TESTING 141
ANTISEPTIC WASHES 142
PHARMACEUTICALS 142
MERCK 142
Boceprivir 142
VERTEX 142
Teleprivir 142
TIBOTEC 143
CEREXA 143
Ceftaroline 143
NXL104 143
BASILEA PHARMACEUTICALS 143
Ceftobiprole 143
Delafloxacin 144
JOHNSON & JOHNSON 144
Doribax 144
CUBIST PHARMACEUTICALS 145
CSA-201 145
CXA183,315 145
TOYAMA CHEMICAL 145
T-705 145
T-3912 145
T-2307 146
GLAXOSMITHKLINE 146
OPTIMER PHARMACEUTICALS 146
Fidaxomicin 146
AURICX 146
BPH-652 146
PFIZER 147
THE MEDICINES COMPANY 147
Oritavancin 147
STERILIZATION AND DISINFECTION 147
SHARKLET TECHNOLOGIES 147
HEALTHCARE FACILITY DESIGN 148
MEDICAL DEVICE DESIGN 148
ONDINE BIOMEDICAL 148
CERAGENIX PHARMACEUTICALS, INC 148
RENAL SEPSIS MICROFILTER 149
CHAPTER TEN: COMPANY PROFILES 150
PHARMACEUTICALS 150
ABBOTT LABORATORIES 150
Business Overview 150
Financials 150
Products 150
ASTELLAS PHARMA, INC 151
Business Overview 151
Financial Information 151
Products 151
ASTRA TECH 152
ASTRAZENECA, PLC 152
Business Overview 152
Financials 152
Products 152
BACTIGUARD, AB 153
Business Overview 153
Financials 153
Products 153
BASILEA PHARMACEUTICA, LTD 153
Business Overview 154
Financials 154
Products 154
BAYER, AG (MILES-BAYER) 154
Business Overview 155
Financials 155
Products 155
BOEHRINGER INGELHEIM, GMBH 155
Business Overview 155
Financials 156
Products 156
BRISTOL-MYERS SQUIBB 156
Business Overview 156
Financials 156
Products 157
CEREXA, INC (FOREST LABORATORIES) 157
Business Overview 157
Financials 157
Products 157
CUBIST PHARMACEUTICALS 158
Business Overview 158
Financials 158
Products 158
ELAN CORPORATION 159
Business Overview 159
Financials 159
Products 160
FOREST LABORATORIES 160
Business Overview 160
Financials 160
Products 160
ELI LILLY AND COMPANY 161
Business Overview 161
Financials 161
Products 161
GILEAD SCIENCES 162
Business Overview 162
Financials 162
Products 162
GLAXOSMITHKLINE 162
Business Overview 162
Financials 163
Products 163
JOHNSON & JOHNSON 163
Business Overview 163
Financial Information 164
Products 164
MEDIMMUNE PHARMACEUTICALS 164
Business Overview 164
Financials 164
Products 165
MERCK 165
Business Overview 165
Financials 165
Products 165
NABI BIOPHARMACEUTICALS 166
Business Overview 166
Financials 166
Products 167
PFIZER 167
Business Overview 167
Financials 167
Products 168
ROCHE PHARMACEUTICALS 168
Business Overview 168
Financials 168
Products 169
SANOFI AVENTIS 169
Business Overview 169
Financials 169
Products 170
SCHERING-PLOUGH 170
THE MEDICINES COMPANY 170
Business Overview 170
Financials 170
Products 170
THERAVANCE 171
Business Overview 171
Financials 171
Products 171
TOYAMA CHEMICAL CO, LTD 172
Business Overview 172
Financials 172
Products 172
VERTEX PHARMACEUTICALS, INC 173
Business Overview 173
Financials 173
Products 173
VIROPHARMA, INC 173
Business Overview 174
Financials 174
Products 174
ENVIRONMENTAL PRODUCTS 174
3M HEALTHCARE, MEDICAL DIVISION 174
Business Overview 174
Financials 175
Products 175
ADVANCED STERILIZATION PRODUCTS 175
Business Overview 175
Financials 175
Products 176
ANDERSEN PRODUCTS, INC 176
Business Overview 176
Financials 176
Products 177
BAXTER INTERNATIONAL 177
Business Overview 177
Financials 177
Products 177
DIVERSEY, INC 178
Business Overview 178
Financials 178
Products 179
ECOLAB 179
Business Overview 179
Financials 179
Products 179
GETINGE USA, INC 180
Business Overview 180
Financials 180
Products 180
PRIMUS STERILIZER CO, INC 181
Business Overview 181
Financials 181
Products 181
RUHOF CORP 181
Business Overview 181
Financials 181
Products 182
STERIGENICS 182
Business Overview 182
Financials 182
Products 182
STERIS CORP 183
Business Overview 183
Financials 183
Products 183
TUTTANAUER USA CO, LTD 184
Business Overview 184
Financials 184
Products 184
ULTRAVIOLET DEVICES, INC 184
Business Overview 184
Financials 185
Products 185
XENEX HEALTHCARE SERVICES 185
Business Overview 185
Financials 185
Products 185
INFECTION CONTROL DEVICES 186
B BRAUN MELSUNGEN, AG 186
Business Overview 186
Financials 186
Products 186
BECTON DICKINSON 187
Business Overview 187
Financials 187
Products 187
BIOMÉRIEUX, INC 188
Business Overview 188
Financials 188
Products 189
CANTEL MEDICAL CORP 189
Business Overview 189
Financials 189
Products 189
CAREFUSION CORP 190
Business Overview 190
Financials 190
Products 191
CEPHEID 191
Business Overview 191
Financials 191
Products 191
CLOROX CO 192
Business Overview 192
Financials 192
Products 192
COLOPLAST GROUP 192
Business Overview 193
Financials 193
Products 193
CONVATEC 193
Business Overview 193
Financial 193
Products 194
COOK MEDICAL 194
Business Overview 194
Financials 194
Products 195
COVIDIEN, PLC 195
Business Overview 195
Financials 195
Products 195
CR BARD 196
Business Overview 196
Financials 196
Products 197
DRAGER MEDICAL, LTD, UK 197
Business Overview 197
Financials 197
Products 198
HOLLISTER, INC 198
Business Overview 198
Financials 198
Products 198
KIMBERLY-CLARK HEALTHCARE 198
Business Overview 198
Financials 199
Products 199
ODINE BIOMEDICAL, INC 199
Business Overview 199
Financials 200
Products 200
TELEFLEX MEDICAL 200
Business Overview 200
Financials 200
Products 201
WELCH ALLYN, INC 201
Business Overview 201
Financials 201
Products 201
To order this report:
Drug and Medication Industry: Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article